We found that in mice bearing MDA-MB-231 tumors with surface Trop-2 expression greater than 4-fold higher than parental tumor cells, SG therapy resulted in tumor regression with significant survival benefit observed despite having intact and functioning DDR pathways. The gene discussed is TACSTD2; the disease is neoplasm.